Table 2. Shows the relationship between selected patients’ demography and 5-year overall survival among women with BC attended at MNH/ORCI between 2016 and 2017.
| Variable | Alive | Dead | p-value |
|---|---|---|---|
| Age groups (N = 256) | |||
| <40 | 11 (19.6) | 45 (80.4) | 0.25 |
| 41–60 | 40 (31.0) | 89 (69.0) | |
| 61–80 | 21 (35.6) | 38 (64.4) | |
| >80 | 4 (33.3) | 8 (66.7) | |
| Disease stage (N = 256) | |||
| IIB | 10 (62.5) | 6 (37.5) | < 0.001 |
| IIIA | 14 (56.0) | 11 (44) | |
| IIIB | 50 (32.1) | 104 (67.9) | |
| IIIC | 2 (22.2) | 7 (77.8) | |
| IV | 0 (0.0) | 50 (100) | |
| Parity (N = 198) | |||
| Nulliparous | 51 (26.6) | 141 (73.4) | 0.71 |
| Parous | 2 (33.3) | 4 (66.7) | |
| Menopausal status (N = 134) | |||
| Premenopausal | 16 (24.2) | 50 (75.8) | 0.16 |
| Postmenopausal | 24 (35.3) | 44 (64.7) | |
| Luminal status (N = 124) | |||
| Luminal A | 26 (47.3) | 29 (52.7) | 0.07 |
| Luminal B | 6 (40.0) | 9 (60.0) | |
| Her-2 enriched | 2 (16.7) | 10 (83.3) | |
| Triple Negative | 11 (26.2) | 31 (73.8) | |